Lyra Therapeutics Inc at William Blair Growth Stock Conference Transcript
Thank you. I think we're going to get started. First of all, welcome, everyone. It's great to see everybody in person. I know we haven't had GSC in a number of years in person. So it's fantastic to see everyone and to see the great attendance this year. For those of you who don't know, my name is Tim Lugo. I'm the head of biotech and pharma research here at William Blair.
And it's my pleasure to welcome Lyra Therapeutics. Maria Palasis will be speaking. She is the CEO of Lyra Therapeutics. Also, Jason Cavalier will be attending the breakout and answer questions, if anyone is concerned about their financial guidance and/or funding of their expanding pipeline. And it's my pleasure to have Lyra here now.
I know it's not a great time in the market for small-cap pharma and biotech. However, Lyra is a great company to look at amongst kind of the turmoil we see in the markets. They have a great lead asset, LYR-201 (sic - see slide 2, "LYR-210"), which has fantastic Phase 2 data, has entered Phase 3. They have a great group of investors after the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |